Analysts Set Option Care Health, Inc. (NASDAQ:OPCH) Price Target at $33.00

Option Care Health, Inc. (NASDAQ:OPCH) has been assigned an average rating of “Moderate Buy” from the eight research firms that are currently covering the company, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $33.00.

A number of equities analysts recently commented on the company. JPMorgan Chase & Co. lifted their price target on Option Care Health from $40.00 to $41.00 and gave the stock an “overweight” rating in a research note on Thursday, March 6th. Barrington Research boosted their price target on Option Care Health from $33.00 to $38.00 and gave the company an “outperform” rating in a report on Thursday, February 27th. Jefferies Financial Group raised Option Care Health from a “hold” rating to a “buy” rating and upped their price target for the company from $26.00 to $35.00 in a research report on Thursday, January 23rd. JMP Securities reaffirmed a “market outperform” rating and issued a $30.00 price objective (down previously from $31.00) on shares of Option Care Health in a report on Friday, January 10th. Finally, Bank of America raised shares of Option Care Health from a “neutral” rating to a “buy” rating and increased their target price for the stock from $26.00 to $33.00 in a report on Monday, January 13th.

Option Care Health Price Performance

Shares of OPCH stock opened at $32.87 on Thursday. The firm has a fifty day moving average of $33.00 and a two-hundred day moving average of $28.50. The firm has a market cap of $5.40 billion, a P/E ratio of 27.62, a P/E/G ratio of 2.30 and a beta of 1.07. Option Care Health has a 1-year low of $21.39 and a 1-year high of $35.53. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.73 and a quick ratio of 1.32.

Insider Buying and Selling at Option Care Health

In related news, insider Michael Bavaro sold 30,996 shares of the stock in a transaction dated Friday, February 28th. The shares were sold at an average price of $33.26, for a total value of $1,030,926.96. Following the sale, the insider now owns 44,974 shares of the company’s stock, valued at $1,495,835.24. This trade represents a 40.80 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.64% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Graypoint LLC bought a new stake in shares of Option Care Health during the fourth quarter valued at approximately $1,161,000. Charles Schwab Investment Management Inc. raised its stake in Option Care Health by 6.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,510,131 shares of the company’s stock valued at $58,235,000 after acquiring an additional 147,054 shares in the last quarter. Global Alpha Capital Management Ltd. raised its stake in Option Care Health by 38.1% during the 4th quarter. Global Alpha Capital Management Ltd. now owns 68,810 shares of the company’s stock valued at $1,596,000 after acquiring an additional 18,992 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new position in Option Care Health during the 4th quarter worth $327,000. Finally, Barclays PLC grew its stake in shares of Option Care Health by 180.1% in the third quarter. Barclays PLC now owns 310,194 shares of the company’s stock worth $9,708,000 after purchasing an additional 199,454 shares in the last quarter. 98.05% of the stock is owned by institutional investors and hedge funds.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.